Table 1.

Prevalence (in millions) of pre-clinical and clinical disease states of Alzheimer’s disease in the United States in 2017 and 2060 based on multistate model [ranges generated by high and low series of transition rates]

	CALENDAR YEAR
DISEASE STATE	2017	2060
Amyloidosis only [state 2]	22.14 [18.70–26.70]	31.90 [28.04–36.75]
Neurodegeneration only [state 3]	8.33 [5.68–9.16]-	13.60 [8.47–16.11]-
Amyloidosis & Neurodegeneration [state 4]	16.23[11.85–21.93]	30.18 [23.49–37.78]
MCI due to Alzheimer’s disease [states 5+6]	2.43 [1.41–4.02]	5.70 [3.61–8.34]
With neurodegeneration	0.66 [0.28–1.51]	1.23 [0.56–2.49]
With Amyloidosis and neurodegeneration	1.77[1.13–2.51]	4.47 [3.05–5.85]
Clinical Alzheimer’s Disease [states 7+8]	3.65[1.70–7.62]	9.30 [4.58–17.82]
Early Stage	2.11 [1.03–4.12]	5.29 [2.73–9.40]
Late Stage	1.54 [0.67–3.50]	4.01 [1.85–8.42]